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Abstract
Background: Fatigue is one of the primary symptoms in lung cancer, with a prevalence of 88.0% in survivors of
cancer, and an even higher prevalence post resection surgery. Effective fatigue control after lung cancer surgery is
important for patient recovery and quality of life. Some studies have shown that acupuncture might be effective in
treating cancer-related fatigue; however, randomized controlled trials (RCTs) of suitable sample size are limited.
Method/design: This is a multi-center, patient-blinded RCT. A total of 320 eligible patients will be recruited in four
centers and randomly assigned to either the acupuncture group or the sham acupuncture group in a 1:1 ratio.
Treatment will be given twice per week for 12 sessions. Treatment will be given at acupoints GV20, GV29, CV12,
CV6, CV4, and bilateral LI4, LR3, SP6, ST36. The primary outcome will be assessed using the Chinese version of The
Brief Fatigue Inventory. The secondary outcomes will be measured using The European Organization for Research
and The Treatment of Cancer Quality of Life Questionnaire, and the Hamilton Rating Scale for Depression. The
primary outcome will be assessed at all main points (baseline, the 3rd week, the 6th week, and at follow up time
points) and the secondary outcomes will be assessed at baseline and the 6th week. Intention-to-treat analysis will
be used in this RCT.
Discussion: This trial protocol provides an example of the clinical application acupuncture treatment in the management
of lung cancer-related fatigue. If the acupuncture treatment protocol confirms that acupuncture is an effective
and safe option for lung cancer-related fatigue, it can be adopted as a standardized treatment.
Trial registration: Chinese Clinical Trial Registry, ChiCTR1900022831. Registered on 27 April 2019.
URL: http://www.chictr.org.cn/showproj.aspx?proj=37823
Keywords: Acupuncture, Lung cancer, Cancer-related fatigue, RCT, Multi-center randomized controlled trial
Background
Cancer is a worldwide health epidemic with ever in-
creasing morbidity and mortality rates. Partially driven
by the modern lifestyle, cancer is currently the second
leading cause of death worldwide [1–3]. Lung cancer
ranks first in the incidence of malignant tumors in
China; about 781,000 people suffer from lung cancer per
year [4]. Cancer-related fatigue (CRF) is a common co-
morbidity of oncological disease, and seriously affects
the quality of life and mental health of patients. In 2000,
the National Comprehensive Cancer Network (NCCN)
guidelines note [5] that CRF is characterized by a feeling
of fatigue and lack of energy and includes physical, emo-
tional, and cognitive fatigue. It is persistent and is not
relieved through rest. It may be caused by cancer itself
or cancer-related treatments, and is not proportional to
activity [5, 6]. A study has shown that the prevalence of
CRF is 88.0% in survivors of cancer [7]. The respiratory
function of patients with lung cancer decreases signifi-
cantly after lung cancer resection, which can lead to
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worsening fatigue. Treatment of symptoms may be help-
ful in lung cancer-related fatigue, such as regulating
immunity, treatment of depression, nutritional support,
improving sleep, and exercise. Yet there are few effective
therapies available for treating CRF. Therefore, it is
imperative to find an effective treatment that is without
side effects.
Acupuncture therapy has been successfully used to
treat many varied diseases for thousands of years. In fact,
some research on acupuncture for lung CRF has
revealed its advantages [8–10], include relieving symp-
toms, improving patient quality of life, and delaying the
progression of cancer. However, most of these studies
are of low value because of flawed methodology, such as
inappropriate duration of treatment, sample size, and
lack of blinding. The lack of objectivity makes the find-
ings of those reports unreliable.
Faced with the limitations of current research, high-
quality evidence is needed to confirm the effectiveness
and safety of acupuncture for lung CRF. Therefore,
through this proposed multi-center, randomized con-
trolled trial (RCT), we aim to obtain evidence on the use
of acupuncture in the treatment of lung CRF. The
findings of this trial will provide useful information; this
will be shared through publication and will provide an
optimal acupuncture treatment protocol for lung CRF.
Hypotheses
This trial aims to prove that acupuncture is an effective
intervention that can relieve fatigue and improve the life
quality of patients with lung cancer after lung cancer re-
section surgery.
Objectives
The objectives of the study are:
1. To assess whether acupuncture is cost-effective in
improving scores on the Brief Fatigue Inventory-
Chinese (BFI-C) and European Organization for Re-
search and Treatment of Cancer Quality of Life
Questionnaire (EORTC QLQ-C30), when compared
with sham acupuncture.
2. To compare the differences in improvement of
mood, measured by the Hamilton Rating Scale for
Depression (HAMD), between the intervention
group and control group.
3. To determine the influence of the credibility of
acupuncture on acupuncture treatment, as assessed
by the Credibility of Treatment Rating Scale (CTRS).
Methods/design
Study design
We propose a multi-center, randomized, sham-controlled,
patient and assessor blinded trial. The trial commence in
four centers after ethical approval has been obtained from
the Institutional Review Board. The clinical trial is
designed and reported following the Consolidated Stan-
dards of Reporting Trials [11] and Standards for Reporting
Interventions in Clinical Trials of Acupuncture guidelines
[12]. Eligible patients will be randomly divided into the
acupuncture group and the sham acupuncture group in a
1:1 allocation ratio. All participants will provide signed
informed consent before proceeding with the trial. The
flow chart of the study process is shown in Fig. 1.
Sample size
The sample size calculation was based on change in BFI-
C scores. According to previous studies [13], we assume
the change is − 2.35 in the acupuncture group and − 2.0
in the sham-acupuncture group; therefore, the mean
difference between two group is 0.35 with standard
deviations of 1.03 and 1.00, and a sample size of 133 per
Fig. 1 Flowchart of the study process. BFI-C, Brief Fatigue Inventory-
Chinese; QLQ-C30, European Organization for Research and Treatment
of Cancer Quality of Life Questionnaire; HAMD, Hamilton Rating Scale
for Depression
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group will provide 80% power to reject the null hypoth-
esis with a significance level of 0.05, using a two-sided,
two-sample, unequal-variance t test. Allowing for a
dropout rate of 20%, a total of 320 participants should
be recruited for this trial.
Recruitment
This multi-center, randomized, sham-controlled, patient
and assessor blinded trial will be conducted in the Shanghai
Yueyang Hospital of Integrated Traditional Chinese and
Western Medicine, Shanghai Municipal Hospital of
Traditional Chinese Medicine, Shanghai Chest Hospital,
and LongHua Hospital Shanghai University of Trad-
itional Chinese Medicine. Participants of the study will
be recruited through the outpatient clinic or inpatient,
hospital-based Wechat advertising, and posters in the
hospital. Any interested patients will be screened by
telephone or on site and consented for the study. After
being informed of the details of this RCT, participants
will be asked to provide signed informed consent, and
deliver it to an independent research assistant. Patients
will be randomly divided into two groups: the acupunc-
ture group (n = 160) and the sham acupuncture group
(n = 160). All participants will undergo 6-week treat-
ment with acupuncture (or sham acupuncture) and a
series of assessments of CRF, free of charge. Timing of
treatment assessments and data collection are as follows
in Table 1.
Inclusion criteria
Participants with the following conditions will be included:
1. Participants in line with interpretation of Chinese
lung cancer treatment guidelines (2015 edition) for
the diagnosis of lung cancer [14]
2. Imaging evidence that supports a diagnosis of lung
adenocarcinoma
3. Resection surgery performed within the last 3–6
months but no chemotherapy
4. Meet the diagnostic criteria for CRF [15] and BFI-C
score > 4
5. Age 18–75 years
6. Karnofsky Performance Status (KPS) score > 80 [16]
7. Able to understand the nature of the study and
willing to give informed consent
8. Capable of providing responses during outcome
measurement
Exclusion criteria
Participants with the following conditions will be
excluded:
Table 1 Timing of treatment assessments and data collection
Study period
Enrollment Baseline Treatment phase Follow-up phase
Timepoint -1 week 0 weeks 3 weeks 6 weeks 4 weeks 12 weeks
Enrollment
Eligibility screen X
Informed consent X
Medical history X
Allocation X
Interventions
Acupuncture X X X
Sham acupuncture X X X
Assessments
Primary outcome
BFI-C X X X X X
Secondary outcomes
EORTC QLQ-C30 X X
HAMD X X
Others
Adverse events X X X
Patients’ satisfaction X
Success of blinding X
BFI-C Brief Fatigue Inventory-Chinese, EORTC QLQ-C30 European Organization for Research and Treatment of Cancer Quality of LifeQuestionnaire, HAMD Hamilton
Rating Scale for Depression
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1. Comorbidities such as serious heart, kidney, or liver
disease
2. Severe mental disorder such as cognitive
impairment
3. Other physiological or pathological causes of fatigue
such as chronic fatigue syndrome (CFS)
4. Acupuncture received within the past 6 months
5. Pregnancy or currently lactating
Randomization and allocation concealment
Stratified block randomization will be used in this experi-
ment. An independent statistician will generate the
randomization sequence using SPSS 23.0. The participants
who meet the criteria will be randomly assigned to one of
the two groups in 1:1 ratio by computer-generated ran-
dom sequences after completion of the baseline assess-
ment. Participants will be randomized in blocks of 4–8 at
each center. The randomization will be concealed by using
opaque envelopes. The treatment allocation codes will not
be revealed until the participants have finished all baseline
assessments and before the first acupuncture treatment.
In order to minimize breaks in coding, the principal inves-
tigator (PI) who designed the trial and research personnel
who perform the outcome assessments will be blinded to
the treatment assignment. Only the acupuncturists will
know which participants belong to which groups.
Blinding
Participants will be informed that they will be randomly
assigned to either acupuncture treatment or
acupuncture-like simulation treatment. Participants will
be asked to wear an eye-patch when they receive treat-
ment: the two groups will receive identical treatment ex-
cept no skin penetration will be involved in the sham
acupuncture group. Therefore, participants and other re-
searchers (the PI, data analysts, outcome assessors, and
statistician) will be blinded to the group allocation. All re-
searchers will be trained before the trial begins, to ensure
the successful implementation of the blinding method.
Intervention protocol
The acupuncture treatment will be conducted after all
participants have given informed consent. All patients
will receive 12 treatments, either acupuncture or sham
acupuncture twice per week for 6 weeks. In each treat-
ment session, every patient will be placed in a separate
space and asked to wear an eye-patch. Each procedure
will last 30 min and will be performed by a trained acu-
puncturist who will be a registered practitioner with
more than 3 years of experience in clinical practice. The
acupuncturist will confirm that the participant has
undergone the assigned procedure. To improve patients’
compliance, all patients will receive the intervention and
assessments by telephone reservation.
The acupuncture procedure will be performed follow-
ing the Guidance of Clinical Practice of Acupuncture
[17]. Before treatment, the patients’ skin will be sterilized
using alcohol wipes, then the experienced acupuncturists
will begin the treatment. In the treatment group, acu-
puncture needles will be standard stainless steel, sterile,
and disposable (0.25 × 40mm and 0.30 × 40mm in
length; Jia Jian, China). The Streitberger placebo-needle
will be used at the same acupoints in the control group.
The methods and acupoints for acupuncture treatment
are shown in Table 2. Any concomitant care or interven-
tion that has the effect of supplementing Qi (traditional
Chinese medicine term) is not allowed to be used during
the treatment and follow-up period, including using
some special herbs and exercising Qi-Gong et al.
The acupuncture group
The acupuncture group will receive real acupuncture
treatment for 6 weeks. According to our previous experi-
ence, Baihui (GV20), Yintang (GV29), Zhongwan (CV12),
Qihai (CV6), Guanyuan (CV4), bilateral Hegu (LI4), bilat-
eral Taichong (LR3), bilateral Sanyinjiao (SP6), and bilat-
eral Zusanli (ST36) will be used as the acupoints for
treatment. Patients will be treated in the supine position
at GV20, CV12, CV6, CV4, and LI4 (with the needle tip
pointing towards the ground), at CV29 and LR3 (with the
needle tip pointing towards the feet), and at SP6 and ST36
(with the needle tip pointing towards the limb extrem-
ities). All the acupoints will be punctured perpendicularly
to the respective depth of 10–30mm, manipulating manu-
ally (including lifting, thrusting, and rotating) until the
patient reports needling sensations (Deqi sensation). The
needles on the bilateral Zusanli (ST36) will be connected
to an SDZ-III Electronic Acupuncture Treatment Instru-
ment (Hwato, China), using continuous wave type stimu-
lation, with a frequency of 2 Hz, and intensity of 2~3mA.
Needles will be retained for 30min.
The control group
The control group will undergo treatment with special
sham acupuncture. We will use a non-invasive placebo
control, the Streitberger placebo-needle. Acupoints will
be the same as in the acupuncture group but without in-
sertion of the needle. Similarly, the electroacupuncture
apparatus (SDZ-III Electronic Acupuncture Treatment
Instrument) will be set beside the patients and connected
to the bilateral Zusanli (ST36), without an electrical pulse.
This set up will remain in place for the next 30min.
Outcome measures
We will assess the primary outcome at baseline, week 3,
post treatment (week 6), and at follow up at the 4th and
12th weeks after the end of treatment. Secondary out-
comes will be assessed at baseline and week 6.
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Primary outcome
Brief Fatigue Inventory-Chinese version (BFI-C)
The change in BFI-C scores will be used to evaluate the
degree and impact of fatigue. The Brief Fatigue Inven-
tory scale is designed by Mendoza [18] and translated by
Wang [19], and it comprises two parts, (the first part
consists of 1–3 items, the second part consists of 4–9
items), and questionnaire items 1–3 are used to assess
the individual’s overall fatigue level over the past 24 h.
The items 4–9 are designed to evaluate the effects of
fatigue on general activities, emotions, walking ability,
normal work (including work and housework), relation-
ship with others, and enjoyment of life. The scale uses
the 10-point scoring method, whereby 0 points indicates
no fatigue and 10 points the most severe fatigue. A
higher score indicates more severe fatigue. According to
the average score, it can be divided into four grades, that
is no fatigue (score 0), mild fatigue (score 1–3), moder-
ate fatigue (score 4–6), and severe fatigue (score 7–10).
The BFI scale has been validated in patients with differ-
ent types of cancer all over the world [19–21]; the struc-
tural validity is 0.81–0.92, and the Cronbach’s coefficient
of the total scale is 0.96. The Chinese version of the BFI
has been proven to have good reliability and validity
[19]. The mean of the change in score on the BFI-C at
week 6 will be analyzed as the primary outcome.
Secondary outcomes
European Organization for Research and Treatment of
Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
The EORTC QLQ-30 is a core scale developed by the
European Organization for Research and Treatment (EO
RTC) for the determination of quality of life in patients
with cancer [22]. It includes a total of 30 entries, which
are divided into 15 domains; among these there are 5
functional domains (body, role, cognition, mood, and so-
cial function), 3 symptom domains (fatigue, pain, and
nausea and vomiting), 1 overall health status/quality of
life area and 6 single entries (each as a domain). The
higher the score for the functional domains and overall
health status, the better the functional status and quality
of life. The higher the score for the symptom domains,
the worse the quality of life. The mean of any change in
score at week 6 will be analyzed.
Hamilton Rating Scale for Depression (HAMD)
The HAMD developed in 1960 [23, 24] is the question-
naire used to describe the severity of cognitive and bod-
ily symptoms of depressive disorders. Each item is rated
on 3-point or 5-point scales. According to the total
score, depression can be divided into four grades: nor-
mal (total score < 7); patient may have depression (total
score 7–17); depression (total score 17–24); and severe
depression (total score > 24). The higher the total score,
the more significant the tendency toward depression.
The mean of any change in score at week 6 will be
analyzed.
Safety assessment
Any adverse events occurring during the trial will be re-
corded by the patients and physicians. Any discomfort,
symptoms, or other diseases will be assessed. All details
of adverse events will be reported in the case report
form. The researcher will interview participants and
write an adverse event report after treatment. The Data
and Safety Monitoring Board and Ethic Review Board
will assess any correlation between the adverse event
and the intervention, and make the final decision as to
whether to continue the study or not. We will analyze
the influence of all events at the end of the trial.
Credibility of Treatment Rating Scale (CTRS)
The CTRS is a scale for assessing the credibility of the
acupuncture treatments. It consists of four items and is
used to assess the participants as “perceived logic of the
treatment,” “confidence in recommending the treatment
to their friends who have similar complaints,” “confi-
dence in the treatment to alleviate their complaint,” and
Table 2 Details of intervention
Intervention group Control group
Acupoints GV20, GV29, CV12, CV6, CV4, LI4, LR3, SP6, ST36 GV20, GV29, CV12, CV6, CV4, LI4, LR3, SP6, ST36
Depth of
insertion
GV20, GV29, LI4, LR3 10 mm No insertion
CV12, SP6, CV6, CV4, ST36 30 mm
Needle type Steel needle (Wuxi Jiajian Medical Co. Ltd. Wuxi, China) Blunt-tip needle (Streitberger placebo-needle)
Needle
sensation
With de-qi sensation Without de-qi sensation
Electric
stimulation
Needle on bilateral ST36 connected to SDZ-III Electronic Acupuncture Treatment
Instrument (Hwato, China). with electric pulse at a frequency of 2.5 Hz and an in-
tensity of 45 mA
Needle on bilateral ST36 connected to SDZ-III Elec
tronic Acupuncture Treatment Instrument (Hwato,
China). without electric pulse
Frequency
and duration
Twice per week for 6 weeks Twice per week for 6 weeks
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“likelihood that the treatment would alleviate their other
complaints.” A lower score indicates greater confidence
in the received treatment [25, 26].
Assessment of blinding
After the final treatment session, the success of the
blinding method will be tested by asking the participants
the following question “When you volunteered for the
study, you were informed that you had an equal chance
of receiving traditional acupuncture or acupuncture-like
simulation treatment. Our study is finished now, which
style acupuncture do you think you are received?” The
participants will be provided with three choices of
response to this question: acupuncture, acupuncture-like
simulation, or uncertain. If participants do not chose
“uncertain”, we will ask the reason why they have made
that assumption [27].
Quality control
The Clinical Research Center of Drugs of Shanghai Uni-
versity of Traditional Chinese Medicine Data Monitoring
Team will be responsible for controlling bias and identi-
fying problems in the project. In order to guarantee the
quality of this study, every acupuncturist in this trial will
be a registered practitioner with 3–5 years of clinical
experience in the practice of acupuncture. Meanwhile, a
qualified clinical trial expert will monitor every trial
center, and regular board meetings will be held to en-
sure the quality of the study process.
Monitoring
According to recommendation of the National Institutes
of Health (NIH), a Data and Safety Monitoring Board
(DSMB) will be formed to monitor the trial progress and
review the safety and quality of the data [28]. The com-
mittee consists of three members, including a senior
acupuncturist, an oncologist, and a statistician (Add-
itional file 2). The DSMB is independent of the proposed
trial and all members will have to declare any conflict of
interest in the trial. Regular meetings will be held during
the trial, to ensure the data are collected scientifically
and ethically. Moreover, the DSMB can ensure partici-
pants are not exposed to unnecessary risks, and has the
right to unblind the study if serious adverse events re-
lated to the intervention occur. The DSMB will provide
data monitoring with access to any interim results and
will make the final decision to terminate the trial if ne-
cessary. It also will identify problems in the project, if
any, make decisions on changing the details of this
protocol, apply for approval from the Ethics Review
Board by written application, and announce the persons
conducting the trial by written notice after approval is
received from the ethics committee. Besides this, a quali-
fied clinical trial expert will be invited to monitor this
study, and the PI will take full responsibility and make
any final decisions.
Clinical trial registration
This RCT was registered in the Chinese Clinical Trial
Registry (ChiCTR1900022831) on 27 April 2019. The
URL is http://www.chictr.org.cn/showproj.aspx?proj=37823
.
Data management
The participant will be interviewed at each time point,
and further cancer care advice will be given at the inter-
view. This procedure will promote retention of partici-
pants and completion of follow-up assessments. All the
original data will be collected by blinded assessors and
double-entered into the electronic data capture system
(EDC). The system will be tested before it is officially
launched to ensure that it meets the trial requirements.
The original data recorded in case report forms will be
entered into the EDC within 1 week after the partici-
pants have finished all the treatments and follow-up
assessments. Codes and initials will be used in the case
report forms, instead of the participant’s information, to
protect the participant’s privacy. If the data are found to
be uncertain, the data supervisor will notify the re-
searcher to respond with a data question form. If neces-
sary, the statistician will send a data question form to
the researcher and the researcher’s answer will be en-
tered on the form. The inspector will then return the
question form to the statistician.
Statistical analysis
Statistical analysis of data will be carried out using SPSS
23.0 software. We will use multiple imputation to ad-
dress any missing data. An independent statistician, who
will be blinded to group allocation, will analyze all data,
including those from any participants who drop out dur-
ing the trial, using the intention-to-treat (ITT) method.
Baseline demographics will be analyzed descriptively.
Changes in BFI-C will be compared between the two
groups as the primary analysis, using repeated measures
analysis of variance (ANOVA (general linear model)).
For the secondary outcomes, scores on the QLQ-C30,
HAMD, and CTRS will be compared between the two
groups using Student’s t test or the Wilcoxon rank-sum
test. All reported P values will be two-sided, and a P
value of less than 0.05 will be considered statistically sig-
nificant. The mean difference and confidence intervals at
the 95% level will also be calculated using SPSS.
Discussion
Fatigue is a typical symptom that is common in lung
cancer and can seriously affect a patient’s quality of life
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and emotional health [29, 30]. CRF is a common condi-
tion that occurs at different stages of oncological disease
(after surgery, treatment with target therapy, etc.) [29–
31]. With the development of complementary and alter-
native medicine, more and more patients with cancer
tend to choose acupuncture as a main treatment to treat
fatigue. Recently, several studies have shown that acu-
puncture can effectively improve the symptoms of CRF
[32–36]. However, there is currently a lack of multi-
center, large-sample, sham-controlled, RCTs in CRF [29,
37]. In this study protocol, we designed a randomized,
multi-center, sham-controlled, patient and assessor
blinded trial (Additional file 1). If the protocol confirms
that acupuncture is effective and safe, it can be imple-
mented for relieving CRF and improving quality of life
in patients with lung cancer.
Because of the nature of acupuncture, there are many
factors that can affect the clinical outcomes, including
individual differences, needle insertion techniques and
duration of the sessions. Our study protocol is based on
literature from textbooks and relevant reports, and on
our previous clinical experience. Traditional acupoints
will be selected for treatment (GV20, GV29, CV12, CV6,
CV4, and bilateral LI4, LR3, SP6, and ST36). Another
advantage is that the same trained acupuncturists will
implement a standardized protocol for point selection
and for the needle insertion, minimizing factors that
might affect the clinical outcomes. The nature of acu-
puncture treatment made double-blinding impossible,
but our design incorporating sham acupuncture allows
blinding of the patient and assessor. Only the acupunc-
turist will know the treatment allocation, but they will
know nothing about the results, and assessors do not
know the treatment allocation before and after the
evaluation of treatment efficacy, thus avoiding the
potential for bias. Another innovation in this study
protocol is the use of the CTRS to assess the influence
of the patients’ perceptions of the credibility of acupunc-
ture on acupuncture treatment.
However, this study protocol still faces several limita-
tions and challenges. The first is the blinding method.
Because of the nature of the clinical trials of acupunc-
ture, it is inevitable that the acupuncturist will know the
treatment allocation. However, the acupuncturists will
be blinded to the results. In order to prevent the acu-
puncturist from accidentally revealing the group alloca-
tion, their interactions with the patients will be limited.
All patients will be asked to wear an eye-patch and
arranged in a separate space during treatments. Overall,
both groups will receive blinding to balance the efficacy
between the two groups. The second limitation is the
application of the acupuncture method. Before the study
begins, all acupuncturists will receive several training
sessions on the standardized protocol for point selection
and needle insertion to ensure the consistency of the
acupuncture techniques. The third limitation is the chal-
lenge of compliance. To solve this problem, we will pro-
vide patients outreach over the Wechat or phone to
arrange the treatment time to improve patients’ attend-
ance. Following completion of the trial, researchers will
conduct follow up by phone to collect data on patients’
final outcomes.
Though there are many challenges, we will strive to
standardize the steps of the trial and the quality of the
trial will be monitored by the DSMB. We hope that this
trial will provide a strong quality of evidence on the effi-
cacy and the safety of acupuncture for treating lung
cancer-related fatigue (CRF). We expect that our find-
ings will advance knowledge in China on the effective-
ness of acupuncture in patients with lung cancer who
have CRF.
Trial status
The first investigators’ meeting took place on 18 No-
vember 2018. The protocol version 2.0, which was
revised on 15 April 2019, was approved by the Ethics
Committee of Yueyang Hospital of Integrated Trad-
itional Chinese and Western Medicine. The RCT is in
preparation now and will launch on 1 June 2019.
Recruitment is expected to end late 2021.
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Abbreviations
ANOVA: Analysis of variance; BFI-C: Brief Fatigue Inventory-Chinese;
CFS: Chronic fatigue syndrome; CN: Conception vessel; CRF: Cancer-related
fatigue; CTRS: Credibility of Treatment Rating Scale; DSMB: Data and Safety
Monitoring Board; EDC: Electronic data capture system; EO RTC: European
Organization for Research and Treatment; EORTC QLQ-C30: European
Organization for Research and Treatment of Cancer Quality of Life
Questionnaire; GV: Governor vessel; HAMD: Hamilton Rating Scale for
Depression; ITT: Intention to treat; KPS: Karnofsky Performance Status;
LI: Yangming large intestine channel of hand; LR: Liver channel of foot
Jueyin; NCCN: National Comprehensive Cancer Network; NIH: National
Institutes of Health; PI: Principal investigator; RCT: Randomized controlled
trial; SP: Spleen meridian of foot Taiyin; ST: Stomach channel of foot-
Yangming
Acknowledgements
We would like to thank Dr Philippa Hazlewood from the International
Education College, Shanghai University of Traditional Chinese Medicine, for
her language editorial support.
Statement
Central ethical approval has been confirmed from the Ethics Committee of
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine
(ref approval no. 2019–034) and we will not begin recruiting at other centers
in the trial until local ethical approval has been obtained. The final version
identifier of this protocol is 2.0, which was modified on 15 April 2019.
Wang et al. Trials          (2019) 20:625 Page 7 of 9
Authors’ contributions
The trial was designed and developed by HGW and SFX. The manuscript was
prepared by ZQW, SSL, and LYW. MZ, JHT, and SFX were responsible for the
methodology and design of the intervention. QQ prepared the tables and
figures. The protocol was carefully revised and edited by XPM and HRL, and
XMJ and DLS contributed the discussion. All authors read and approved the
final manuscript.
Funding
This work was supported by National Basic Research Program of China (973
Program) (grant number 2015CB554500). The funding body has no role in
study design, data collection, data analysis, data interpretation, or writing of
the report.
Availability of data and materials
The trial results will be published through publication in a peer-reviewed sci-
entific paper and poster or oral presentations in conferences. All data will be
available from the 3rd month to the 3rd year after publication of the results
with researchers who provide a methodologically sound proposal to achieve
aims in the approved proposal. The trial data will be available from the corre-
sponding author upon reasonable request.
Ethics approval and consent to participate
This multi-center RCT was approved by the Ethics Committee of Yueyang
Hospital of Integrated Traditional Chinese and Western Medicine on 25 April
2019 (certificate number 2019–034). The purpose, procedures, and potential
risks of the RCT will be explained clearly to the participants. All participants
will give their written informed consent to the research assistant before join-
ing the RCT.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Author details
1Yueyang Hospital of Integrated Traditional Chinese and Western Medicine,
Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China.
2Shanghai Research Institute of Acupuncture and Meridian, Shanghai
University of Traditional Chinese Medicine, Shanghai 200030, China.
3Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai
University of Traditional Chinese Medicine, Shanghai 200071, China. 4Stark
Neurosciences Research Institute & Department of Anatomy and Cell Biology,
Indiana University School of Medicine, Indianapolis, IN 46202, USA. 5Longhua
Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai
200032, China. 6Shanghai Chest Hospital, Shanghai 200030, China.
Received: 20 May 2019 Accepted: 4 September 2019
References
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer
statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J.
Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.
3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;
68(1):7–30.
4. Chen W, Sun K, Zheng R, Zeng H, Zhang S, Xia C, Yang Z, Li H, Zou X, He J.
Cancer incidence and mortality in China, 2014. Chin J Cancer Res. 2018;
30(1):1–12.
5. Berger AM, Abernethy AP, Atkinson A, Barsevick AM, Breitbart WS, Cimprich
B, Cleeland C, Eisenberger MA, Escalante CP, Jacobsen PB, et al. NCCN
Clinical practice guidelines in oncology on cancer-related fatigue. J Natl
Compr Cancer Netw. 2010;8(8):904-31.
6. Dodd M. Cancer-Related Fatigue. Cancer Investig. 2009;18(1):97.
7. Sha FEI, Zhuang S, Zhou LI, Zhang L, Yang Y, Zhang S, Jiang YI, Qiu G, Chen
C, Zheng J, et al. Biomarkers for cancer-related fatigue and adverse
reactions to chemotherapy in lung cancer patients. Mol Clin Oncol. 2015;
3(1):163–6.
8. Cheng C-s, L-y C, Z-y N, C-y Z, Chen H, Chen Z, Zhu X-Y, Xie J.
Acupuncture for cancer-related fatigue in lung cancer patients: a
randomized, double blind, placebo-controlled pilot trial. Support Care
Cancer. 2017;25(12):3807–14.
9. He XR, Wang Q, Li PP. Acupuncture and Moxibustion for Cancer-related
Fatigue: a Systematic Review and Meta-analysis. Asian Pacific Journal of
Cancer Prevention Apjcp. 2013;14(5):3067-74.
10. Moran JM, Puerto-Parejo LM, Leal-Hernandez O, Sánchez Fernández A,
Pedrera-Zamorano JD. Acupuncture for cancer-related fatigue in lung
cancer patients: methodological and statistical issues. Support Care Cancer.
2018;27(1):1–2.
11. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ,
Elbourne D, Egger M, Altman DG. CONSORT 2010 Explanation and
elaboration: updated guidelines for reporting parallel group randomised
trials. Bmj. 2010;340(mar23 1):c869.
12. MacPherson H, Altman DG, Hammerschlag R, Li Y, Wu T, White A, Moher D.
Revised standards for reporting interventions in clinical trials of acupuncture
(STRICTA): extending the CONSORT statement. Chin J Evid Based Med. 2010;
10(10):1228–39.
13. Lian W. Clinical research of traditional chinese medicine (TCM) syndrome
differentiation and acupuncture treatment on cancer related fatigue (CRF).
Guangzhou: Guangzhou University of Chinese Medicine; 2015.
14. Xiuyi Z, Yuankai S, Jinming Y. Chinese lung cancer treatment guidelines
(2015 edition). Chinese J Oncol. 2015;37(1):67–79.
15. Plummer AL. International classification of diseases, tenth revision, clinical
modification for the pulmonary, critical care, and sleep physician. Chest.
2015;148(5):1353–60.
16. Mor V, Laliberte L, Morris JN, Wiemann M. The Karnofsky Performance Status
Scale: an examination of its reliability and validity in a research setting.
Cancer. 1984;53(9):2002–7.
17. Witt CM. Clinical research on acupuncture - Concepts and guidance on
efficacy and effectiveness research. Chin J Integr Med. 2011;17(3):166–72.
18. Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Judy K,
Wendt M, Stephen L, Huber MS. The rapid assessment of fatigue severity in
cancer patients. Am Cancer Soc. 1999;85(5):1186–96.
19. Wang XS, Hao XS, Wang Y, Guo H, Jiang YQ, Mendoza TR, Cleeland CS.
Validation study of the Chinese version of the Brief Fatigue Inventory (BFI-
C). J Pain Symptom Manag. 2004;27(4):322–32.
20. Catania G, Bell C, Ottonelli S, Marchetti M, Bryce J, Grossi A, Costantini M.
Cancer-related fatigue in Italian cancer patients: validation of the Italian
version of the Brief Fatigue Inventory (BFI). Support Care Cancer. 2013;21(2):
413–9.
21. Paramita N, Nusdwinuringtyas N, Nuhonni SA, Atmakusuma TD, Ismail I,
Mendoza TR, Cleeland CS. Validity and reliability of Brief Fatigue Inventory
(BFI)-Indonesian version in cancer patients. J Pain Symptom Manag. 2016;
52(5):744–51.
22. Chie WC, Yang CH, Hsu C, Yang PC. Quality of life of lung cancer patients:
validation of the Taiwan Chinese version of the EORTC QLQ-C30 and QLQ-
LC13. Qual Life Res. 2004;13(1):257–62.
23. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry.
1960;23:56–62.
24. Cusin C, Yang H, Yeung A, Fava M. Rating Scales for Depression. In:
Handbook of clinical rating scales and assessment in psychiatry and mental
health; 2009. p. 7–35.
25. Devilly GJ, Borkovec TD. Psychometric properties of the credibility
expectancy questionnaire. J Behav Ther Exp Psychiatry. 2000;31:73–86.
26. Vincent C. Credibility assessment in trials of acupuncture. Complement Med
Res. 1990;4(1):8-11.
27. Lao L, Bergman S, Hamilton GR, Langenbery P, Beran B. Evaluation of
acupuncture for pain control after oral surgery: a placebo-controlled trial.
Arch Otolaryngol Head Neck Surg. 1999;125:567–72.
28. Data and Safety Monitoring Board (DSMB) guidelines [https://www.nidcr.nih.
gov/research/human-subjects-research/interventional-studies/data-and-
safety-monitoring-board-guidelines]. Accessed 4 Nov 2019.
29. Lau CH, Wu X, Chung VC, Liu X, Hui EP, Cramer H, Lauche R, Wong SY, Lau
AY, Sit RS, et al. Acupuncture and related therapies for symptom
management in palliative cancer care: systematic review and meta-analysis.
Med (Baltimore). 2016;95(9):e2901.
30. Iwase S, Kawaguchi T, Tokoro A, Yamada K, Kanai Y, Matsuda Y, Kashiwaya Y,
Okuma K, Inada S, Ariyoshi K, Miyaji T, Azuma K, Ishiki H, Unezaki S,
Yamaguchi T. Assessment of Cancer-Related Fatigue, Pain, and Quality of
Wang et al. Trials          (2019) 20:625 Page 8 of 9
Life in Cancer Patients at Palliative Care Team Referral: A Multicenter
Observational Study (JORTC PAL-09). Plos One. 2015;10(8):e0134022.
31. Dagnelie P, Pijls-Johannesma M, Lambin P, Beijer S, De Ruysscher D,
Kempen G. Impact of fatigue on overall quality of life in lung and breast
cancer patients selected for high-dose radiotherapy. Ann Oncol. 2007;18(5):
940–4.
32. Deng G, Chan Y, Sjoberg D, Vickers A, Yeung KS, Kris M, Straus D, Cassileth
B. Acupuncture for the treatment of post-chemotherapy chronic fatigue: a
randomized, blinded, sham-controlled trial. Support Care Cancer. 2013;21(6):
1735–41.
33. Berger AM. Does the strength of evidence support recommending
acupuncture to relieve cancer-related fatigue? Ann Palliat Med. 2013;
2(1):11–3.
34. Grant SJ, Smith CA, de Silva N, Su C. Defining the quality of acupuncture.
Integr Cancer Ther. 2015;14(3):258–70.
35. Johnston MF, Hays RD, Subramanian SK, Elashoff RM, Axe EK, Li JJ, Kim I,
Vargas RB, Lee J, Yang L, et al. Patient education integrated with
acupuncture for relief of cancer-related fatigue randomized controlled
feasibility study. BMC Complement Altern Med. 2011;11:49.
36. Molassiotis A, Bardy J, Finnegan-John J, Mackereth P, Ryder DW, Filshie J,
Ream E, Richardson A. Acupuncture for cancer-related fatigue in patients
with Breast cancer: a pragmatic randomized controlled trial. J Clin Oncol.
2012;30(36):4470–6.
37. Javdan B, Cassileth B. Acupuncture research at Memorial Sloan Kettering
Cancer Center. J Acupunct Meridian Stud. 2015;8(3):115–21.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Wang et al. Trials          (2019) 20:625 Page 9 of 9
